Trade PURETECH HEALTH PLC ORD 1P - PRTC CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0330 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023252% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001334% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | GBP | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United Kingdom of Great Britain and Northern Ireland | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.4445 |
| Open | 1.4465 |
| 1-Year Change | -21.66% |
| Day's Range | 1.4185 - 1.4625 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Feb 21, 2025 | 1.4185 | -0.0280 | -1.94% | 1.4465 | 1.4625 | 1.4125 |
| Feb 20, 2025 | 1.4445 | 0.0020 | 0.14% | 1.4425 | 1.4585 | 1.4125 |
| Feb 19, 2025 | 1.4485 | 0.0100 | 0.70% | 1.4385 | 1.4725 | 1.4185 |
| Feb 18, 2025 | 1.4485 | -0.0240 | -1.63% | 1.4725 | 1.4725 | 1.4485 |
| Feb 17, 2025 | 1.4505 | 0.0020 | 0.14% | 1.4485 | 1.4525 | 1.3985 |
| Feb 14, 2025 | 1.4485 | -0.0140 | -0.96% | 1.4625 | 1.4725 | 1.4185 |
| Feb 13, 2025 | 1.4285 | -0.0020 | -0.14% | 1.4305 | 1.4705 | 1.4285 |
| Feb 12, 2025 | 1.4465 | 0.0180 | 1.26% | 1.4285 | 1.4625 | 1.4285 |
| Feb 11, 2025 | 1.4325 | 0.0000 | 0.00% | 1.4325 | 1.4465 | 1.3945 |
| Feb 10, 2025 | 1.4485 | 0.0100 | 0.70% | 1.4385 | 1.4605 | 1.4225 |
| Feb 7, 2025 | 1.4325 | -0.0360 | -2.45% | 1.4685 | 1.4765 | 1.4185 |
| Feb 6, 2025 | 1.4685 | 0.0180 | 1.24% | 1.4505 | 1.4905 | 1.4405 |
| Feb 5, 2025 | 1.4505 | -0.0220 | -1.49% | 1.4725 | 1.4865 | 1.4405 |
| Feb 4, 2025 | 1.4765 | -0.0020 | -0.14% | 1.4785 | 1.5060 | 1.4765 |
| Feb 3, 2025 | 1.5020 | 0.0515 | 3.55% | 1.4505 | 1.5040 | 1.4345 |
| Jan 31, 2025 | 1.4920 | 0.0315 | 2.16% | 1.4605 | 1.4925 | 1.4605 |
| Jan 30, 2025 | 1.4705 | 0.0260 | 1.80% | 1.4445 | 1.4845 | 1.4425 |
| Jan 29, 2025 | 1.4525 | 0.0320 | 2.25% | 1.4205 | 1.4925 | 1.4085 |
| Jan 28, 2025 | 1.4185 | 0.0000 | 0.00% | 1.4185 | 1.4605 | 1.4185 |
| Jan 27, 2025 | 1.4365 | 0.0360 | 2.57% | 1.4005 | 1.4605 | 1.3805 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Puretech Health plc Company profile
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines targeting serious diseases that result from dysfunctions in the nervous, immune, and gastrointestinal systems. The company is developing a digital medicine platform for the treatment and assessment of cognitive dysfunction across various neurological and psychiatric indications; therapies to treat a range of acute and chronic inflammatory disorders; microbiome-derived immune modulators for maternal and paediatric health; novel approach to oral delivery of biologics, vaccines, and other drugs; platform to address androgenetic alopecia; mechanotherapeutics to treat obesity, and other chronic diseases related to the gastrointestinal pathway; muscarinic receptor agonist programme for the treatment of psychosis and cognition, including schizophrenia and Alzheimer''s; monoclonal antibody-based therapeutic to treat pancreatic cancer and other solid tumors; voice-based technology platform for monitoring and diagnosing mental and physical medical conditions, such as depression, Alzheimer''s disease, multiple sclerosis, and Parkinson''s disease; platform and products that seek to explore and leverage the health potential of music; therapies for immune-mediated and infectious diseases based on rationally-defined consortium of human microbiome-derived bacteria; and novel antibody and cell therapies for treating cancer. It is also developing a milk exosome-based technology designed to enable the oral administration of biologics, nucleic acids, and complex small molecules; and a lipid prodrug technology to enable lymphatic targeting. In addition, the company''s medical device programme is developing a non-invasive neurostimulation treatment for psychiatric disorders, including depression and bipolar disorder. PureTech Health plc was incorporated in 2015 and is headquartered in Boston, Massachusetts.| Industry: | Biotechnology & Medical Research (NEC) |
6 Tide Street
Suite 400
BOSTON
MASSACHUSETTS 02210
US
News
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025
Ripple XRP price prediction: Third-party price target
Discover the ripple (XRP) price predictions for 2025 and beyond, with analyst price targets and CFDs trading strategies on Capital.com
15:29, 6 February 2025
Apple (AAPL) stock price forecast: third-party price target
We looked at the forecasts for Apple stock in 10 years to see where the price would likely be at that point and the challenges the company could face. Read more.
11:22, 6 February 2025
FARTCOIN price prediction: Third-party price target
Read our FARTCOIN price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:18, 29 January 2025
MELANIA coin ($MELANIA) price prediction: Third party price target
Read our MELANIA crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts.
11:33, 22 January 2025
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:52, 22 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025People also watch
Still looking for a broker you can trust?
Join the 690,000+ traders worldwide that chose to trade with Capital.com